Does the prophylactic use of Palivizumab in premature patients with Down Syndrome in respiratory syncytial virus infection reduce the hospitalization rate? An integrative review
DOI:
https://doi.org/10.33448/rsd-v13i1.44288Keywords:
Down Syndrome; Bronchiolitis; Palivizumab.Abstract
Introduction: Acute viral bronchiolitis (AVB) is determined as the first episode of wheezing in children under 24 months. The main agent is the respiratory syncytial virus, responsible for the high hospitalization rates. Among the main risk factors are age, prematurity, Cardiopathies and most importantly, Down Syndrome. This genetic condition increases vulnerability in respiratory infections, resulting from abnormality in the immune system and airways. To reduce hospitalization rates, Palivizumab, an antibody that inhibits the entry and replication of RSV in high-risk individuals, is used. Objective: To evaluate whether the use of Palivizumab in patients with Down syndrome reduces the risk and/or length of hospitalization for AVB. Methodology: This is an integrative review, researching on PubMed, BVS and Cochrane Library databases, containing articles from the last 10 years that include premature children under 2 years and with Down Syndrome. Results: Seven papers were selected from 67 publications. Conclusion: The prophylactic Palivizumab in patients with Down Syndrome shows a reduction in RSV hospitalizations. However, there are gaps in the data in other aspects such as the length of hospitalization, need for supplemental oxygen, time in the ICU and mechanical ventilation. Therefore more research is needed to address these points.
References
Barr, F. E., & Graham, B. S. (2023a) Respiratory syncytial virus infection: Clinical features and diagnosis. UpToDate. https://www.uptodate.com/. Acesso em:03 maio 2023.
Barr, F. E., & Graham, B. S. (2023b) Respiratory syncytial virus infection: Prevention in infants and children. UpToDate. https://www.uptodate.com/. Acesso em: 03 maio 2023.
Brooks, G. F. et al. (2012) Microbiologia médica de Jawaetz, Melnick e Adelberg. (25a ed.), AMGH.
Garegnani, L., Styrmisdóttir, L., Roson Rodriguez, P., Escobar Liquitay, C. M., Esteban, I., & Franco, J. V. (2021). Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. The Cochrane database of systematic reviews, 11(11), CD013757. https://doi.org/10.1002/14651858.CD013757.pub2
Group, T. I.-R. S. (1998) Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics, 102(3), 531-537
Kashiwagi, T., Okada, Y., & Nomoto, K. (2018). Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan. Paediatric drugs, 20(1), 97–104. https://doi.org/10.1007/s40272-017-0264-y
Kimura, T., Takeuchi, M., & Kawakami, K. (2020). Utilization and efficacy of palivizumab for children with Down syndrome. Pediatrics international : official journal of the Japan Pediatric Society, 62(6), 677–682. https://doi.org/10.1111/ped.14157
Luna, M. S., Manzoni, P., Paes, B., Baraldi, E., Cossey, V., Kugelman, A., Chawla, R., Dotta, A., Rodríguez Fernández, R., Resch, B., & Carbonell-Estrany, X. (2020). Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. Paediatric respiratory reviews, 33, 35–44. https://doi.org/10.1016/j.prrv.2018.12.001
Manzoni, P., Paes, B., Lanctôt, K. L., Dall'Agnola, A., Mitchell, I., Calabrese, S., Maule, M., Girardi, E., Harimoto, T., & Li, A. (2017). Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study. The Pediatric infectious disease journal, 36(1), 2–8. https://doi.org/10.1097/INF.0000000000001340
Murray, P. R., Rosenthal, K., & Pfaller, M. A. (2014) Microbiologia Médica, (7a ed.), Elsevier.
Notario G, et al. (2014) Respiratory syncytial virus-related hospitalization in premature infants without bronchopulmonary dysplasia: subgroup efficacy analysis of the IMpact-RSV trial by gestational age group. Pediatric Health Med Ther, (5), 43-48.
Okamoto, K., Morio, T., Nakamura, Y., Hataya, H., Mizuta, K., & Mori, M. (2021). Hospitalisations due to respiratory syncytial virus infection in children with Down syndrome before and after palivizumab recommendation in Japan. Acta paediatrica (Oslo, Norway: 1992), 110(4), 1299–1306. https://doi.org/10.1111/apa.15641.
Ostermaier, K. K. (2023) Down syndrome: Clinical features and diagnosis. UpToDate. 2023. https://www.uptodate.com/. Acesso em: 03 maio 2023.
Simon, A., Gehrmann, S., Wagenpfeil, G., & Wagenpfeil, S. (2018). Palivizumab use in infants with Down syndrome-report from the German Synagis™ Registry 2009-2016. European journal of pediatrics, 177(6), 903–911. https://doi.org/10.1007/s00431-018-3142-x
Stein, R. T., Bont, L. J., Zar, H., Polack, F. P., Park, C., Claxton, A., Borok, G., Butylkova, Y., & Wegzyn, C. (2017). Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis. Pediatric pulmonology, 52(4), 556–569. https://doi.org/10.1002/ppul.23570
Trabulsi, L. R., Alberthum, F. (2008) Microbiologia. (5a ed.), Atheneu.
Paes, B., Mitchell, I., Li, A., & Lanctôt, K. L. (2012). Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. European journal of pediatrics, 171(5), 833–841. https://doi.org/10.1007/s00431-011-1654-8
Paes, B., Mitchell, I., Yi, H., Li, A., Lanctôt, K. L., & CARESS Investigators (2014). Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab. The Pediatric infectious disease journal, 33(2), e29–e33. https://doi.org/10.1097/INF.0000000000000019
Piedra, P. A., & Stark, A. R. (2023a) Bronchiolitis in infants and children: Clinical features and diagnosis. UpToDate. https://www.uptodate.com/. Acesso em: 03 maio 2023.
Piedra, P. A., & Stark, A. R. (2023b) Bronchiolitis in infants and children: Treatment, outcome, and prevention. UpToDate. https://www.uptodate.com/. Acesso em: 03 maio 2023.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Luiz Guilherme Figueira ; Alan das Neves Junior; Ana Clara Ferreira Rodovalho; Amanda Triano de Almeida ; Carolina Abreu Raghiant; Ana Lúcia Lyrio de Oliveira; Luciene Lovatti Almeida Hemerly Elias
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
